Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,721 to 2,740 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication | 157 of 1,342 153 of 1,342 | 0.3 points -2.1 to 2.7 | 2,684 | NCT01907269 A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care |
| Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms | 143 of 788 334 of 1,889 | 0.5 points -2.6 to 3.8 | 2,677 | NCT03442322 Optimizing Care for Patients With Dementia |
| Transdisciplinary Approach vs Multidisciplinary Approach: Rejection of Care | 131 of 788 302 of 1,889 | 0.6 points -2.3 to 3.8 | 2,677 | NCT03442322 Optimizing Care for Patients With Dementia |
| Transdisciplinary Approach vs Multidisciplinary Approach: Wandering | 88 of 788 117 of 1,889 | 5.0 points 2.6 to 7.6 | 2,677 | NCT03442322 Optimizing Care for Patients With Dementia |
| Transdisciplinary Approach vs Multidisciplinary Approach: Physical Restraints Use | 3 of 786 102 of 1,887 | -5.0 points -6.2 to -3.8 | 2,673 | NCT03442322 Optimizing Care for Patients With Dementia |
| Arm I:Sentinel Node Resection+Conventional Axillary Dissection vs Arm II: Sentinel Node Resection Followed by Node Examination: Morbidity - Number of Participants With Residual Arm Tingling | 175 of 1,329 90 of 1,343 | 6.5 points 4.2 to 8.7 | 2,672 | NCT00003830 Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer |
| Cilostazol vs Aspirin: Number of Patients With First Recurrence of Cerebral Infarction | 72 of 1,337 88 of 1,335 | -1.2 points -3.0 to 0.6 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of Haemorrhagic Event | 23 of 1,337 57 of 1,335 | -2.5 points -3.9 to -1.3 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: Numbers of Patients With First Occurence of Stroke | 82 of 1,337 119 of 1,335 | -2.8 points -4.8 to -0.8 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease | 86 of 1,337 103 of 1,335 | -1.3 points -3.2 to 0.7 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: Number of Deaths From Any Cause | 13 of 1,337 13 of 1,335 | -0.0 points -0.8 to 0.8 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events | 138 of 1,337 186 of 1,335 | -3.6 points -6.1 to -1.1 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Cilostazol vs Aspirin: serious adverse events | 372 of 1,337 433 of 1,335 | -4.6 points -8.1 to -1.1 | 2,672 | NCT00234065 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2) |
| Transdisciplinary Approach vs Multidisciplinary Approach: Falls | 326 of 785 750 of 1,887 | 1.8 points -2.3 to 5.9 | 2,672 | NCT03442322 Optimizing Care for Patients With Dementia |
| HIV Self-testing vs Information Only: Newly Identified HIV Infections | 25 of 1,325 11 of 1,340 | 1.1 points 0.2 to 2.0 | 2,665 | NCT02067039 Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP) |
| Transdisciplinary Approach vs Multidisciplinary Approach: Unintended Weight Loss | 125 of 781 302 of 1,884 | -0.0 points -3.0 to 3.1 | 2,665 | NCT03442322 Optimizing Care for Patients With Dementia |
| Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events | 81 of 1,326 270 of 1,334 | -14.1 points -16.7 to -11.6 | 2,660 | NCT00096278 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer |
| Immediate Monitoring vs Delayed Monitoring: Incidence of Newly Diagnosed AF in the Immediate vs Delayed Monitoring Group | 53 of 1,366 12 of 1,293 | 3.0 points 1.8 to 4.2 | 2,659 | NCT02506244 mHealth Screening to Prevent Strokes |
| NanoFlu vs Fluzone Quadrivalent: deaths from any cause | 8 of 1,333 8 of 1,319 | -0.0 points -0.7 to 0.6 | 2,652 | NCT04120194 Phase 3 Pivotal Trial of NanoFlu™ in Older Adults |
| NanoFlu vs Fluzone Quadrivalent: serious adverse events | 136 of 1,333 125 of 1,319 | 0.7 points -1.5 to 3.0 | 2,652 | NCT04120194 Phase 3 Pivotal Trial of NanoFlu™ in Older Adults |
Code
curl "https://conductscience.org/api/comparisons/v1?page=137"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=137
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01907269-d287b278",
"title": "Video-based Intervention vs Usual Care: Number of Participants That Initiate an Osteoporosis Prescription Medication",
"summary": "157 of 1342 against 153 of 1342; risk difference 0.3 points, 95% interval -2.1 to 2.7; NCT01907269, A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care",
"record": "/library/comparisons/NCT01907269-d287b278",
"nct_id": "NCT01907269",
"kind": "outcome",
"participants": 2684,
"risk_difference": {
"value": 0.002980625931445602,
"lower": -0.021265352642068185,
"upper": 0.027231853512111368
},
"group_1": "157 of 1,342",
"group_2": "153 of 1,342",
"difference": "0.3 points",
"interval": "-2.1 to 2.7",
"trial_title": "A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care"
},
{
"id": "NCT03442322-503daa11",
"title": "Transdisciplinary Approach vs Multidisciplinary Approach: Behavioral Symptoms",
"summary": "143 of 788 against 334 of 1889; risk difference 0.5 points, 95% interval -2.6 to 3.8; NCT03442322, Optimizing Care for Patients With Dementia",
"record": "/library/comparisons/NCT03442322-503daa11",
"nct_id": "NCT03442322",
"kind": "outcome",
"participants": 2677,
"risk_difference": {
"value": 0.004658952578782294,
"lower": -0.02634263735014975,
"upper": 0.03755539202981919
},
"group_1": "143 of 788",
"group_2": "334 of 1,889",
"difference": "0.5 points",
"interval": "-2.6 to 3.8",
"trial_title": "Optimizing Care for Patients With Dementia"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=138",
"request_id": "WiDkBrMG8PbCQdgE"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant